Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:SBPH

Spring Bank Pharmaceuticals (SBPH) Stock Price, News & Analysis

Spring Bank Pharmaceuticals logo

About Spring Bank Pharmaceuticals Stock (NASDAQ:SBPH)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.21
$10.39
52-Week Range
N/A
Volume
N/A
Average Volume
177,606 shs
Market Capitalization
$122.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of a range of cancers and inflammatory diseases using its proprietary small molecule nucleotide platform. The company is developing SB 11285, a next-generation immunotherapeutic cyclic dinucleotide for the treatment of selected cancers; novel STING antagonist compounds for the treatment of autoimmune and inflammatory diseases; and novel platform to enable the targeted delivery of payload molecules. It has a collaboration agreement with with Roche to explore the co-administration of SB 11285. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.

Receive SBPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spring Bank Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SBPH Stock News Headlines

Capital One Bank Review
Discover Bank Review (August 2024)
The “supermetal” that could power AI
While the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the story. This next-gen supermetal, dubbed “black glass,” could solve the power crisis stalling AI’s growth. It’s 400x stronger than steel, conducts electricity better than copper, and costs just a few bucks to produce.
When will interest rates go down?
Man stabbed during street fight in Spring Bank West
See More Headlines

SBPH Stock Analysis - Frequently Asked Questions

Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) posted its quarterly earnings results on Sunday, November, 8th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.06.

Spring Bank Pharmaceuticals (SBPH) raised $14 million in an initial public offering on Friday, May 6th 2016. The company issued 1,100,000 shares at a price of $12.00-$14.00 per share. Dawson James Securities served as the underwriter for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Spring Bank Pharmaceuticals investors own include Intelsat (I), AMC Entertainment (AMC), Bank of America (BAC), Fossil Group (FOSL), Associated British Foods (ABF), Apollo Global Management (APO) and Chaarat Gold (CGH).

Company Calendar

Last Earnings
11/08/2020
Today
6/01/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SBPH
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$24.10 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.16 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$122.94 million
Optionable
Not Optionable
Beta
1.07
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:SBPH) was last updated on 6/1/2025 by MarketBeat.com Staff
From Our Partners